Skip to main content
  • Tweet
  • Share on Facebook
  • Share on Google +1
  • Share via Email
  • Contact
  • Glossary
  • Subscribe
  • Search

PATH's Malaria Vaccine Initiative

Accelerating Malaria Vaccine Development

  • Malaria vaccines & biologics
    • Need for vaccines
      • Malaria vaccine roadmap
      • Preferred product characteristics
    • Malaria parasite life cycle
  • R&D
    • First-generation vaccines
    • Next-generation vaccines
      • Pre-erythrocytic vaccine candidates
      • Blood-stage vaccine candidates
      • Transmission-blocking vaccine candidates
      • Combination vaccine candidates
    • Monoclonal antibodies
  • RTS,S
    • Piloting RTS,S
      • Cost of delivering RTS,S
      • Public health impact and cost-effectiveness
      • Qualitative study on vaccine use
      • Case control studies
    • Clinical trial history of RTS,S
      • RTS,S use in seasonal settings
    • Expanded use of RTS,S
  • Access
    • Preparing for malaria vaccine decisions
      • Global policy and regulatory pathways
      • Decision-making framework
        • The decision-making framework for malaria vaccines
        • Economic analysis
        • Public health impact analysis
        • Sociocultural research
    • Financing
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Publications
    • Videos
    • Reports
    • Past projects
  • News
    • Press releases
    • Perspectives
  • About us
    • Donors
    • Contact us
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Tools for advocates
    • Propose a project
  • Malaria vaccines & biologics
    • Need for vaccines
      • Malaria vaccine roadmap
      • Preferred product characteristics
    • Malaria parasite life cycle
  • R&D
    • First-generation vaccines
    • Next-generation vaccines
      • Pre-erythrocytic vaccine candidates
      • Blood-stage vaccine candidates
      • Transmission-blocking vaccine candidates
      • Combination vaccine candidates
    • Monoclonal antibodies
  • RTS,S
    • Piloting RTS,S
      • Cost of delivering RTS,S
      • Public health impact and cost-effectiveness
      • Qualitative study on vaccine use
      • Case control studies
    • Clinical trial history of RTS,S
      • RTS,S use in seasonal settings
    • Expanded use of RTS,S
  • Access
    • Preparing for malaria vaccine decisions
      • Global policy and regulatory pathways
      • Decision-making framework
    • Financing
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Publications
    • Videos
    • Reports
    • Past projects
  • News
    • Press releases
    • Perspectives
  • About us
    • Donors
    • Contact us
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Tools for advocates
    • Propose a project
  • Home
  • News
  • Press releases

Press releases

  • PATH welcomes WHO recommendation of a second malaria vaccine for young children

    2 Oct 2023
  • Dramatic reductions in malaria cases and deaths continue over five years with seasonal malaria vaccine-drug combination

    22 Aug 2023
  • Phased expansion of malaria vaccine use begins in more areas in Africa

    7 Mar 2023
  • PATH welcomes WHO prequalification of the first malaria vaccine

    6 Sep 2022
  • PATH welcomes US$ 5 million grant to expand malaria vaccine access in Ghana, Kenya, and Malawi

    19 Apr 2022
  • PATH welcomes commitment by Gavi board to finance wider rollout of the world’s first malaria vaccine, RTS,S

    2 Dec 2021
  • PATH applauds WHO recommendation for broader use of first malaria vaccine

    6 Oct 2021
  • PATH welcomes remarkable results from clinical trial combining RTS,S/AS01 malaria vaccine with Seasonal Malaria Chemoprevention

    25 Aug 2021
  • PATH welcomes landmark financing agreement for GSK’s malaria vaccine

    4 Aug 2021
  • GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine

    27 Jan 2021
  • Milestone study identifies immune markers that may help predict success of vaccination with RTS,S/AS01 malaria vaccine

    22 Jul 2020
  • PATH receives new five-year contract from USAID for malaria vaccine research and development

    7 Jul 2020

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • next ›
  • last »

PATH Washington DC

455 Massachusetts Avenue NW, Suite 1000

Washington, DC 20001 | USA 

Tel: 202.822.0033

Fax: 202.457.1466

Email: mvi_info [at] path.org

PATH Headquarters

2201 Westlake Avenue, Suite 200

Seattle, WA 98121 | USA 

Tel: 206.285.3500

Fax: 206.285.6619

Email: info [at] path.org

Website: www.path.org

Follow us

Mail
Twitter
  • Privacy policy
  • Copyright policy
  • Terms of use
© 2023 PATH
Website by Manta Ray Media